Benzinga | Aug 4, 2021 04:41PM EDT

Fate Therapeutics Q2 EPS $(0.58) Misses $(0.53) Estimate, Sales $13.41M Up From $5.46M YoY

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 65.71 percent decrease over losses of $(0.35) per share from the same period last year. The company reported $13.41 million in sales this quarter. This is a 145.42 percent increase over sales of $5.46 million the same period last year.